| Delineation of Hypoxic Regions in Lung
Cancer by Positron EmissionTomography |
Principal Investigator:Farrokh Dehdashti, M.D.
Contact for further information:Helen
Kaemmerer [(314) 362-7026]
Purpose:This study is designed to determine
the feasibility of imaging hypoxic regions of human
lung cancer with 60Cu-ATSM.
A new hypoxic imaging tracer, 60Cu-labeled
diacetyl-bis(N4-
methylthiosemicarbazone (60Cu-ATSM),
has been developed here at the Mallinckrodt Institute of
Radiology, Washington University. We now propose to apply the
use of 60Cu-ATSM
with
imaging by positron emission tomography (PET) in 20 patients with non-small
cell lung cancer.
The presence of hypoxic tumor cells is known to be an important cause of
resistance to radiation
therapy. The ability to detect and quantify hypoxia in individual human
tumors could affect the
selection of therapy, such as the use of the specific antihypoxia treatment
regimens. Few
techniques exist to measure hypoxia in human tumors. Tumor hypoxia can be
directly measured
with polarographic oxygen electrodes; however, this technique is invasive,
technically demanding,
limited to evaluation of readily accessible tumors, and prone to sampling
errors because of tumor
oxygenation heterogeneity.
The Specific Aims of the proposal are to: (1) study
the kinetics, uptake and trapping of 60Cu-
ATSM in lung cancer; and (2) compare the uptake and trapping of 60Cu-ATSM
with tumor
response to radiation therapy. Tumor response will be determined by change
in the tumor volume
and metabolism (as measured by volumetric CT and PET with [18F]fluorodeoxyglucose,
respectively). We hypothesize that the amount of trapping of 60Cu-ATSM
within tumors will be
inversely correlated with tumor response to radiation therapy. Successful
completion of this
research study will provide the data needed to design a larger study to
assess hypoxia and its
impact on treatment of malignant neoplasms.
(In addtion to the table below, also see the arms of the study)
Inclusion criteria:
- Biopsy proven/suspected lung cancer
- Primary lesion size <=
2 cm
- Adult patient, 18 years of age or greater
- Not pregnant or nursing
- Able to lie flat for PET imaging
- Able to give informed consent
- The patient is scheduled to undergo a clinically indicated FDG-PET study for evaluation of
their proven/suspected lung cancer. |
Exclusions criteria:
- Patients with prior radiation therapy to the same region, or systemic chemotherapy
- Patients unable to give informed consent
